



TROP2 ADCs for NSCLC: What Community Oncologists Need to Know



This activity is provided by Med Learning Group

This activity is supported by educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

TROP2 ADCs for NSCLC: What Community Oncologists Need to Know

PROGRAM CHAIR

Benjamin P. Levy, MD

Associate Professor of Oncology
Johns Hopkins School of Medicine
Baltimore, Maryland
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital
Washington, DC, USA

FACULTY PRESENTERS

Maen A. Hussein, MD

Medical Oncologist & Hematologist
President Florida society of clinical oncology
Assistant prof UCF college of medicine
Medical Director, Value-Based Care
Florida Cancer Specialists & Research Institute
The Villages, FL

Jennifer W. Carlisle, MD

Assistant Professor
Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, GA

PROGRAM OVERVIEW

This new educational series is intended for community oncologists who diagnose and care for patients with non-small cell lung cancer (NSCLC), primarily in the USA, but also globally. It aims to help these providers better understand the role of trophoblast cell-surface antigen 2 (TROP2) in the pathophysiology of NSCLC and the rationale behind targeting TROP2 in select patients with heavily treated advanced NSCLC. The series will also highlight the advances in developing TROP2-targeting antibody-drug conjugates (ADCs), discuss pivotal clinical trial data showing their efficacy and safety stratified by tumor histology and molecular genetics, and discuss their unique adverse event profiles.

Clinicians will learn to develop personalized treatment plans by increasing their familiarity with emerging and recently approved TROP2-targeting ADCs in specific populations of patients with NSCLC and will further recognize the importance of incorporating a multidisciplinary approach to management of the unique adverse events associated with TROP2 ADCs.

TARGET AUDIENCE

This educational activity is intended for community oncologists who diagnose and care for patients with non-small cell lung cancer, primarily in the USA, but also globally.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

- Describe the role of TROP2 signaling in the pathophysiology of NSCLC and the rationale for TROP2-targeted ADCs
- Analyze the latest clinical trial data for TROP2-targeted ADCs to inform treatment selection for patients with NSCLC
- Summarize the adverse event monitoring requirements for TROP2-targeted ADCs and best practices for managing emerging events in patients with NSCLC

JOINT ACCREDITATION STATEMENT



In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this virtually live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hours.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group (MLG) must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)

Faculty Member	Disclosures
Benjamin P. Levy, MD	Consulting Fees: AstraZeneca, DSI, Janssen, Merck, Pfizer
Maen A. Hussein, MD	Consulting Fees: Abbvie; AstraZeneca; AVEO; BeiGene; E.R. Squibb & Sons, LLC; Incyte; Janssen Biotech; Janssen Scientific Affairs; MorphoSys; Pfizer; PharmaEssentia; Stemline Therapeutics
Jennifer W. Carlisle, MD	Consulting Fees: Amgen, AstraZeneca, Catalyst, Eli Lilly, Novocure Contracted Research: Amgen, Black Diamond, Chipscreen, Clinagen, Daiichi Sankyo, Genentech, Pfizer

All relevant financial relationships have been mitigated.

Content Review

The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity

The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.

Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.

Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.

Anita Misra-Press, PhD, Medical Director for Med Learning Group, has nothing to disclose.

Shannon Mutch MS, RN, OCN, has nothing to disclose.

A medical reviewer from CME Peer Review LLC, has nothing to disclose.

Abigail Dill, Program Manager for Med Learning Group, has nothing to disclose.

Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity.

In order to obtain a certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.

Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at <http://medlearninggroup.com/privacy-policy/>

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group, prior to participating, at info@medlearninggroup.com



This activity is provided by Med Learning Group

This activity is supported by educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.